Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus
August 15, 2016 7:00 AM EDT
TEL AVIV, Israel, Aug. 15, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today reported financial results and provided a business update for the second quarter and six month period ended June 30, 2016.
The second quarter of 2016 was marked by further progress in the clinic with our lead oncology product candidate, VB-111, which has shown evidence of benefit in multiple tumor types, said Dror Harats, Chief Executive Officer of VBL Therapeutics. The positive results we announced... More
August 11, 2016 6:45 AM EDT
TEL AVIV, Israel, August 11, 2016 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.
Mr. Serlin joined the Company in 2009 as its Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who joined the Company in 2004, and has served as its Chief Executive Officer since 2010. Â Dr. Savitsky will serve as... More
